BRPI0915284A2 - Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral - Google Patents

Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral

Info

Publication number: BRPI0915284A2
Authority: BR; Brazil
Prior art keywords: treating; oral; mammal; pharmaceutical composition; release formulation
Prior art date: 2008-06-30

Application number

BRPI0915284-9A

Other languages

English (en)

Inventor

Harry E Gruber

Douglas J Jolly

Kay Olmstead

Original Assignee

Tocagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-30

Filing date

2009-06-30

Publication date

2015-08-04

2009-06-30 Application filed by Tocagen Inc filed Critical Tocagen Inc

2015-08-04 Publication of BRPI0915284A2 publication Critical patent/BRPI0915284A2/pt

2020-01-14 Publication of BRPI0915284B1 publication Critical patent/BRPI0915284B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BRPI0915284A 2008-06-30 2009-06-30 composição farmacêutica oral, e, uso de uma composição farmacêutica BRPI0915284B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7714208P	2008-06-30	2008-06-30
PCT/US2009/049322 WO2010002937A1 (en)	2008-06-30	2009-06-30	Formulations of 5-fluorocytosine and uses thereof

Publications (2)

Publication Number	Publication Date
BRPI0915284A2 true BRPI0915284A2 (pt)	2015-08-04
BRPI0915284B1 BRPI0915284B1 (pt)	2020-01-14

Family

ID=41466310

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0915284A BRPI0915284B1 (pt)	2008-06-30	2009-06-30	composição farmacêutica oral, e, uso de uma composição farmacêutica

Country Status (11)

Country	Link
US (4)	US9320738B2 (pt)
EP (1)	EP2306823A4 (pt)
JP (3)	JP6092514B2 (pt)
KR (2)	KR101950635B1 (pt)
CN (2)	CN102076215A (pt)
AU (1)	AU2009267052B2 (pt)
BR (1)	BRPI0915284B1 (pt)
CA (1)	CA2724740C (pt)
IL (3)	IL209385A (pt)
MX (2)	MX337213B (pt)
WO (1)	WO2010002937A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2386646B1 (en)	1998-10-01	2016-12-21	University Of Southern California	Gene delivery system and methods of use
MX337213B (es)	2008-06-30	2016-02-17	Tocagen Inc	Formulaciones de 5-fluorocitosina y usos de las mismas.
US8829173B2 (en)	2008-09-26	2014-09-09	Tocagen Inc.	Recombinant vectors
JP5684130B2 (ja)	2008-09-26	2015-03-11	トカジェンインコーポレーテッド	組換えベクター
JP5923037B2 (ja)	2009-06-17	2016-05-24	トカジェンインコーポレーテッド	複製可能レトロウイルスベクターの産生細胞
WO2011057176A1 (en) *	2009-11-06	2011-05-12	Forest Laboratories Holding Limited	Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2012058673A2 (en)	2010-10-31	2012-05-03	Tocagen Inc.	Enhanced cancer treatment and monitoring using recombinant vectors
WO2012104834A1 (en) *	2011-02-03	2012-08-09	Pharmedica Ltd.	New oral dissolving films for insulin administration, for treating diabetes
WO2013004658A1 (en) *	2011-07-01	2013-01-10	Transgene Sa	Formulations of 5-fluorocytosine and uses thereof.
CN102579450B (zh) *	2012-02-10	2013-07-24	上海市嘉定区南翔医院	5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
EP2668945A1 (de) *	2012-06-01	2013-12-04	Bayer Technology Services GmbH	Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
EP3623478A1 (en)	2012-10-25	2020-03-18	Tocagen Inc.	Retroviral vector with mini-promoter cassette
US9642921B2 (en)	2012-12-20	2017-05-09	Tocagen Inc.	Cancer combination therapy and recombinant vectors
WO2017040815A1 (en)	2015-09-04	2017-03-09	Tocagen Inc.	Recombinant vectors comprising 2a peptide
CA3056603A1 (en) *	2017-03-14	2018-09-20	Memorial Sloan Kettering Cancer Center	Labeling, isolation, & analysis of rna from rare cell populations
US20190380965A1 (en) *	2018-06-15	2019-12-19	Hemant N. Joshi	Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine
CA3143952A1 (en) *	2019-02-22	2020-08-27	Candel Therapeutics, Inc.	Gmci and ddri combination therapy for treating cancer
CN115516833B (zh)	2020-03-18	2025-01-03	马维尔以色列(M.I.S.L.)有限公司	网络设备中的分组缓冲溢出
CN111937887B (zh) *	2020-07-15	2021-09-07	南京师范大学	5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1142891B1 (en)	1991-03-06	2007-05-02	Emory University	Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B
FI980901A7 (fi)	1998-04-23	1999-10-24	Orion Yhtymae Oyj	Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
EP2386646B1 (en)	1998-10-01	2016-12-21	University Of Southern California	Gene delivery system and methods of use
EE05022B1 (et) *	1999-03-31	2008-06-16	Janssen Pharmaceutica N.V.	Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
US6677155B1 (en) *	1999-04-22	2004-01-13	The General Hospital Corporation	Triple hybrid amplicon vector systems to generate retroviral packaging lines
GB2368846B (en)	1999-07-08	2004-08-25	Univ California	Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
JP4021627B2 (ja) *	2000-03-22	2007-12-12	株式会社東芝	遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用
WO2002000213A1 (en)	2000-06-23	2002-01-03	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US8071740B2 (en)	2000-11-17	2011-12-06	Vascular Biogenics Ltd.	Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7186699B2 (en) *	2003-06-03	2007-03-06	Cell Genesys, Inc.	Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CN1244321C (zh) *	2003-06-26	2006-03-08	李勇	用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片
US20050049207A1 (en)	2003-09-03	2005-03-03	Kaufmann Doug A.	Method of treating and preventing cancer
EP1771158A4 (en) *	2004-07-02	2008-03-12	Advancis Pharmaceutical Corp	TABLET FOR PULSE DISTRIBUTION
FR2874325B1 (fr)	2004-08-19	2006-10-20	Sanofi Synthelabo	Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US7968698B2 (en)	2005-05-25	2011-06-28	The Regents Of The University Of California	Optimized core promoters and uses thereof
JPWO2007069358A1 (ja) *	2005-12-14	2009-05-21	キッセイ薬品工業株式会社	新規胃内滞留製剤
CN101085355B (zh) *	2007-06-20	2012-01-25	山东大学	5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法
US20090068287A1 (en)	2007-09-12	2009-03-12	Susan Welsh	Novel topical formulations of flucytosine and uses thereof
US9314524B2 (en)	2007-12-31	2016-04-19	Calla Therapeutics Llc	Topical formulations of Flucytosine
MX337213B (es) *	2008-06-30	2016-02-17	Tocagen Inc	Formulaciones de 5-fluorocitosina y usos de las mismas.
JP5684130B2 (ja)	2008-09-26	2015-03-11	トカジェンインコーポレーテッド	組換えベクター
US8829173B2 (en)	2008-09-26	2014-09-09	Tocagen Inc.	Recombinant vectors
CA2805941A1 (en)	2010-08-13	2012-02-16	Pioneer Hi-Bred International, Inc.	Methods and compositions for targeting sequences of interest to the chloroplast

2009
- 2009-06-30 MX MX2010014256A patent/MX337213B/es active IP Right Grant
- 2009-06-30 WO PCT/US2009/049322 patent/WO2010002937A1/en not_active Ceased
- 2009-06-30 AU AU2009267052A patent/AU2009267052B2/en not_active Ceased
- 2009-06-30 KR KR1020177036825A patent/KR101950635B1/ko not_active Expired - Fee Related
- 2009-06-30 EP EP09774387A patent/EP2306823A4/en not_active Withdrawn
- 2009-06-30 MX MX2016002131A patent/MX366570B/es unknown
- 2009-06-30 CA CA2724740A patent/CA2724740C/en not_active Expired - Fee Related
- 2009-06-30 BR BRPI0915284A patent/BRPI0915284B1/pt not_active IP Right Cessation
- 2009-06-30 JP JP2011516833A patent/JP6092514B2/ja not_active Expired - Fee Related
- 2009-06-30 CN CN200980125558XA patent/CN102076215A/zh active Pending
- 2009-06-30 KR KR1020117002457A patent/KR101813721B1/ko not_active Expired - Fee Related
- 2009-06-30 US US13/001,516 patent/US9320738B2/en active Active
- 2009-06-30 CN CN201710036517.XA patent/CN107029220A/zh active Pending
2010
- 2010-11-17 IL IL209385A patent/IL209385A/en active IP Right Grant
2014
- 2014-11-07 JP JP2014227208A patent/JP6170896B2/ja not_active Expired - Fee Related
2016
- 2016-04-22 US US15/136,056 patent/US9889133B2/en active Active
- 2016-06-27 IL IL246473A patent/IL246473B/en active IP Right Grant
2017
- 2017-07-03 JP JP2017130096A patent/JP2017214398A/ja active Pending
- 2017-11-21 IL IL255813A patent/IL255813A/en unknown
2018
- 2018-02-07 US US15/891,243 patent/US10449194B2/en active Active
2019
- 2019-10-16 US US16/654,318 patent/US11191764B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR101950635B1 (ko)	2019-05-20
US10449194B2 (en)	2019-10-22
KR20110039544A (ko)	2011-04-19
IL246473B (en)	2018-06-28
AU2009267052B2 (en)	2013-07-11
CA2724740C (en)	2017-02-21
AU2009267052A1 (en)	2010-01-07
US20160235751A1 (en)	2016-08-18
KR20180004279A (ko)	2018-01-10
US20110268720A1 (en)	2011-11-03
IL209385A0 (en)	2011-01-31
US9320738B2 (en)	2016-04-26
JP2011526918A (ja)	2011-10-20
US20190015414A1 (en)	2019-01-17
MX366570B (es)	2019-07-12
IL209385A (en)	2016-10-31
MX2010014256A (es)	2011-07-01
US9889133B2 (en)	2018-02-13
MX337213B (es)	2016-02-17
CN102076215A (zh)	2011-05-25
KR101813721B1 (ko)	2017-12-29
JP6170896B2 (ja)	2017-07-26
WO2010002937A1 (en)	2010-01-07
US20200281929A1 (en)	2020-09-10
IL255813A (en)	2018-01-31
EP2306823A1 (en)	2011-04-13
CN107029220A (zh)	2017-08-11
JP6092514B2 (ja)	2017-03-08
CA2724740A1 (en)	2010-01-07
JP2017214398A (ja)	2017-12-07
EP2306823A4 (en)	2012-09-26
US11191764B2 (en)	2021-12-07
JP2015063533A (ja)	2015-04-09
BRPI0915284B1 (pt)	2020-01-14

Publication	Publication Date	Title
BRPI0915284A2 (pt)	2015-08-04	Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral
BR112012008854A2 (pt)	2015-09-22	combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BRPI0921687A2 (pt)	2015-08-18	Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0908503A2 (pt)	2015-09-29	partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BRPI0905733A2 (pt)	2015-12-01	"composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0923384A2 (pt)	2016-06-07	composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular
BRPI0921317A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0909780A2 (pt)	2015-08-11	Composições e métodos para liberação de fármaco
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0907162A2 (pt)	2015-07-07	Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0908596A2 (pt)	2015-09-15	formulação e composição farmacêutica de liberação prolongada
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0812521A2 (pt)	2015-06-23	Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0809655A2 (pt)	2014-10-07	Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0917358A2 (pt)	2015-11-17	formulação farmacêutica de liberação controlada e método.
BRPI0909691A8 (pt)	2018-01-02	composto, método para preparar um composto, e, composição farmacêutica
BRPI0907977A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BR112015010501A2 (pt)	2017-07-11	composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BRPI1014865A2 (pt)	2016-05-03	"composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-03-26	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-07-16	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-19	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-01-14	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-04	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 12A ANUIDADE.
2021-08-24	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2626 DE 04-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.